Peroxisomal lipid degradation via β-and α-oxidation in mammals

…, PP Van Veldhoven, M Casteels - Cell biochemistry and …, 2000 - Springer
Peroxisomal β-oxidation is involved in the degradation of long chain and very long chain fatty
acyl-(coenzyme A)CoAs, long chain dicarboxylyl-CoAs, the CoA esters of eicosanoids, 2-…

[HTML][HTML] Call for a dedicated European legal framework for bacteriophage therapy

…, R Lavigne, S Jennes, D De Vos, M Casteels… - Archivum immunologiae …, 2014 - Springer
The worldwide emergence of antibiotic resistances and the drying up of the antibiotic
pipeline have spurred a search for alternative or complementary antibacterial therapies. …

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine

…, S Jennes, M Zizi, R Lavigne, M Casteels… - Archivum immunologiae …, 2012 - Springer
For practitioners at hospitals seeking to use natural (not genetically modified, as appearing
in nature) bacteriophages for treatment of antibiotic-resistant bacterial infections (…

A mouse model for Zellweger syndrome

…, E Baumgart, P Carmeliet, M Casteels, M Fransen… - Nature …, 1997 - nature.com
The cerebro-hepato-renal syndrome of Zellweger is a fatal inherited disease caused by
deficient import of peroxisomal matrix proteins. The pathogenic mechanisms leading to extreme …

Phytosterolemia in children with parenteral nutrition—Associated cholestatic liver disease

…, A Bowron, KA Mills, A Massoud, M Casteels… - Gastroenterology, 1993 - Elsevier
Background: Lipid emulsions used for parenterai nutrition (PN) contain phytosterols. Our
hypothesis was that these phytosterols can accumulate and contribute to cholestatic liver …

[HTML][HTML] Managed entry agreements for oncology drugs: lessons from the European experience to inform the future

K Pauwels, I Huys, S Vogler, M Casteels… - Frontiers in …, 2017 - frontiersin.org
Objectives: The aim of this study is to conduct an analysis on the regulation and application
of managed entry agreements (MEA) for oncology drugs across different European countries…

[HTML][HTML] Insights into European drug shortages: a survey of hospital pharmacists

K Pauwels, S Simoens, M Casteels, I Huys - PloS one, 2015 - journals.plos.org
Drug shortages are a complex and global phenomenon. When a drug cannot be delivered at
the moment of patient demand, every stakeholder in the health care system is affected. The …

[HTML][HTML] Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

K Pauwels, I Huys, M Casteels, S Simoens - BMC health services research, 2014 - Springer
Background Drug shortages are a global problem. While extensively studied in the United
States, numbers about drug shortages in European countries are scarce. This study aims to …

[HTML][HTML] Breakdown of 2-hydroxylated straight chain fatty acids via peroxisomal 2-hydroxyphytanoyl-CoA lyase: a revised pathway for the α-oxidation of straight chain …

…, GP Mannaerts, PP Van Veldhoven, M Casteels - Journal of Biological …, 2005 - ASBMB
… were measured in 20 mm Hepes-NaOH, pH 7.2, 25 μm BSA, 50 μm radioactive substrate, …
volume of 250 μl containing 50 mm Tris-HCl, pH 7.5, 6.6 μm BSA, 0.8 mm MgCl 2 , and 20 μ…

Causes of drug shortages in the legal pharmaceutical framework

…, S Simoens, L Hombroeckx, M Casteels… - Regulatory Toxicology …, 2015 - Elsevier
Introduction Different causes of drug shortages can be linked to the pharmaceutical legal
framework, such as: parallel trade, quality requirements, economic decisions to suspend or …